Maxwell,
Hottod clarified a little while back that the licencing agreement with ACAD doesn't allow them to use NNZ-2591 for Retts in Nth America (and possibly ROW?). In fact doing so would be a breach of the agreement.
From my limited understanding, the approval of Tofinetide / Daybue will make the FDA path easier for NNZ-2591 pending positive trial results (of which there appears to be early indications this is even better than Trof). NEU has learnt much from Trof FDA process so I suspect we'll see quicker approval pathway.
BTW - as at 6th March there were 182k shorted Neu stocks and I'd be surprised if this didn't increased significantly over the last week. there's going to be a few shorters cancelling their chauffeured drivers and hiring electric scooters to get home (if they still own it that is).
Maxwell,Hottod clarified a little while back that the licencing...
-
- There are more pages in this discussion • 6,943 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |